The University of Colorado Anschutz Gates Institute Achieves First-in-U.S. FDA Clearance for Campus-Built CAR T-Cell Therapy

“This work was built on the seminal findings of Craig Jordan’s laboratory, identifying CD64 as a…

Bayesian reasoning in health care: When to refuse medical tests

New AI-powered capabilities from RLDatix and real-world case studies from leading health systems address healthcare’s most…

The real problem with AI in medicine and drug development

Artificial intelligence is rapidly acquiring a reputation as an unreliable, even dangerous, force in medicine and…

Listen: What the Vaccine Schedule Whiplash Means for Your Kids – KFF Health News

New AI-powered capabilities from RLDatix and real-world case studies from leading health systems address healthcare’s most…

Prevention is going to overtake treatments by 2040 – Express Healthcare

MILWAUKEE, April 2, 2026 /PRNewswire/ –Agrace, the largest Wisconsin-based nonprofit hospice, has expanded to serve the…

The hidden link between chronic stress and oral health

In health care, we are trained to measure what we can quantify. We check blood pressure,…

True metabolic healing requires more than just prescribing expensive peptides [PODCAST]

Subscribe to The Podcast by KevinMD. Watch on YouTube. Catch up on old episodes! Internal medicine…

GOP Mulls More Health Cuts – KFF Health News

The Host Recent polling finds that health costs are a top worry for much of the…

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma

FPI achieved for first-in-class combination of IDE849 (DLL3 TOP1 ADC) and IDE161 (PARG inhibitor). IDE161 (PARG)…

RISE highlights connected data, early intervention

RISE National 2026 brought together health plan leaders, policymakers, and industry partners to examine how Medicare…